Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland
By LabMedica International staff writers Posted on 23 Jan 2023 |
Siemens Healthineers (Erlangen, Germany) has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders. Siemens has been active in Swords since 1966, supplying medical diagnostic equipment to hospitals and laboratories. The site currently manufactures hematology and immunoassay analyzers and supports the continuous innovation of current and new products and the development of laboratory automation software, exported to more than 50 countries across all continents. Siemens will be making a multi-million-euro investment in the site, enabling clinicians to optimize patient care by bringing new levels of precision, efficiency and reliability to the diagnostic laboratories that serve them.
The investment by Siemens will span multiple years and more than double the existing engineering team, transforming the site into an innovation hub, growing knowledge, providing new training opportunities and developing a pool of expertise in immunoassay technology. The center will push the boundaries of science and engineering. Improvements to existing diagnostic techniques will enhance disease detection capabilities with the goal of delivering faster, higher precision results with improved patient insights. This will help to meet the extremely high throughput and complex needs of hospitals and laboratories in Ireland as well as globally. The project is supported by the Irish government through IDA Ireland.
“The investment at Swords will build on our existing expertise in healthcare manufacturing, adding a critical research and development focus," states Dr Dennis Gilbert, Head of R&D for Siemens Healthineers Diagnostics. "Partnering with IDA has enabled us to move forward in ways that would not have otherwise been feasible and will allow us to pioneer breakthroughs in healthcare, helping hospitals and laboratories across the globe to diagnose disease more effectively and efficiently.
Related Links:
Siemens Healthineers
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics